Olaparib Maintenance Did Not Improve PFS, OS in Platinum-Sensitive NSCLC

CheckMate 9LA Combination Effective in Advanced NSCLC Despite PD-L1 Expression, TMB Status

PACIFIC-R: Findings Reflect Clinical Reality of Consolidation Therapy in Stage III NSCLC

Symposium Chairs Reflect on Current Status, Next Steps for Lung Cancer Screening on a Global Scale

The “Holy Grail” of Lung Cancer Research: Bring the Immune System into Every Tumor

Could the Daunting Biology of Small-Cell Lung Cancer Provide the Key to Elucidating Drug Resistance?

Mutation or Amplification: Who MET the Expectations?

RET Therapy for NSCLC, a New Generation of Inhibitors

Statistical Design Flexibility Versus Optimism: The Example of KEYNOTE-604

The Multitude of Options for First-Line Therapy for EGFR-Mutated Lung Cancer

The Current Role of Combination Maintenance Therapy (Pemetrexed and Bevacizumab) in the Era of Immunotherapy

Dr. Kazuhiko Nakagawa Discusses RELAY Study Data, Implications for Practice